An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia
for Schizophrenia Disorders
7 locations incl. Bellflower
Sponsor: Collaborative Neuroscience Research, LLC
Sex: All·Age: 18 - 65
Code: NCT06924255·Phase 4·Not Yet Recruiting·Listed Apr 2025